Register for Upcoming LLS Program on Acute Lymphoblastic Leukemia

The Leukemia & Lymphoma Society is sponsoring a free telephone and web education program on the subject of acute lymphoblastic lymphoma (ALL).

The event, titled "ALL: Update on Diagnosis and Treatment," is set to be held on Feb. 17.

This free program will run from:

  • 10 a.m. to 11 a.m. PST
  • 11 a.m. to 12 p.m. MST
  • 12 p.m. to 1 p.m. CDT
  • 1 p.m. to 2 p.m. EST

Minnesota doctor to lead discussion

The guest speaker is Mark R. Litzow, MD. Dr. Litzow is a professor of medicine and a hematologist at the Mayo Clinic in Rochester, Minnesota.

The topics Dr. Litzow will cover in the program include:

  1. How acute lymphoblastic leukemia (ALL) is diagnosed.
  2. The role of clinical trials in the advancement of ALL treatment.
  3. Current treatment options for newly diagnosed and relapsed/refractory patients.
  4. The role of cytogenetics in treatment.
  5. Side effects management.
  6. The importance of open communication with your healthcare team.

To register online for this free program, click here.

To register by phone, please call (866) 992-9950, ext. 315.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap